Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Novo Nordisk stock slumped Wednesday after saying it expects compounded versions to undercut sales of its obesity drug, ...

Plenty of folks have been using GLP-1s — generic knockoffs of popular weight loss drugs such as Ozempic and Zepbound — to jump-start their health journeys lately. But those folks could be in for bad ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Investing.com -- Hims & Hers Health (NYSE: HIMS) stock edged lower on Tuesday, extending its 10% decline following disappointing earnings, as Novo Nordisk (NYSE: NVO) announced 14 new lawsuits ...

FT reports on SEBI’s call for structural reforms after Jane Street ‘manipulation’ while BBC highlights urban India’s new ...

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...